On July 1, 2026 Caris Life Sciences (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, reported the commercial launch of Caris Detect, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Caris Detect is engineered to push the boundaries of what is possible in early cancer detection. Using ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing and advanced artificial intelligence, the test analyzes a broad spectrum of molecular and biological signals associated with cancer, offering a more comprehensive approach than technologies that rely on limited genomic snapshots. Caris Detect’s intended goal is to replace other outdated screening methods as the new standard of care for early detection of cancer.
"Early detection remains one of the most urgent and consequential challenges in oncology," said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences. "Caris Detect represents a major step forward in our mission to transform cancer care through the most advanced molecular science available. By combining unmatched biological depth with sophisticated AI, we are giving physicians and patients a powerful new tool to help identify cancer earlier and support more informed clinical decisions."
Unlike earlier approaches that evaluate only a narrow subset of genomic changes, Caris Detect examines the full breadth of genomic and molecular signals, including DNA, RNA and other biological patterns. This deeper, more comprehensive analysis is designed to improve confidence in identifying cancer signals at their earliest stages, when intervention may have the greatest impact.
Caris Detect is powered by Caris’ expansive molecular profiling database, which includes more than one million cases and over 50 billion molecular markers. This unparalleled dataset enables highly sophisticated AI models to detect subtle signals associated with early-stage disease across multiple cancer types.
The launch of Caris Detect builds on data from the Caris Detect ACHIEVE 1 study, which demonstrated strong performance characteristics in detecting cancer signals across multiple cancer types. This data supports Caris Detect as a tool in Caris’ vision to redefine early detection and improve patient outcomes.
Caris continues to advance its early detection platform through ongoing research and future study milestones designed to further strengthen the clinical evidence base and expand the test’s capabilities over time.
Individuals may learn more about Caris Detect by visiting CarisDetect.com, where information regarding eligibility, physician involvement and the testing process is provided.
(Press release, Caris Life Sciences, JUL 1, 2026, View Source [SID1234669040])